|
12.01.2005 13:02:00
|
Applied Biosystems/MDS Sciex Introduce New Mass Spectrometer for Small
Applied Biosystems/MDS Sciex Introduce New Mass Spectrometer for Small Molecule Quantification Studies New System Brings Unparalleled Sensitivity and Accuracy to Drug Development Studies
Applied Biosystems (NYSE:ABI), an Applera Corporation business, together with its partner MDS Sciex (NYSE:MDZ)(TSX:MDS), today announced the release of the API 5000(TM) LC/MS/MS System, the latest addition to its API family of triple quadrupole analyzers. The API 5000(TM) LC/MS/MS System brings the most sensitive and accurate mass spectrometer to the market for small molecule quantification, which is essential for DMPK(1) and ADMET(2) studies. The system sets a new industry standard by achieving an average nine-fold increase in sensitivity and four-fold improvement in signal-to-noise ratio over other commercially available systems. The instrument will be unveiled to customers in demonstrations around the globe during the coming weeks.
"Pharmaceutical development and clinical research organizations require better tools for critical safety and efficacy studies. The improved sensitivity provided by the API 5000(TM) LC/MS/MS System increases the ability to assay a drug candidate, its metabolites or contaminants," said Catherine M. Burzik, President of Applied Biosystems. "This system can enable these groups to make better decisions during the costly process of bringing new drugs to market."
"The innovative QJet(TM) ion guide, introduced in the API 5000(TM) LC/MS/MS System, captures more ions and focuses the ion beam with high efficiency for improving ion transmission, yielding unparalleled sensitivity," said Andy Boorn, President of MDS Sciex. "This combination permits the use of smaller sample sizes, conserving often limited material for additional studies. When paired with the Turbo V(TM) ion source, users can easily increase flow rates and throughput without a corresponding loss in signal."
"Applied Biosystems/MDS SCIEX is proud to offer the next generation platform for bioanalytical research," said Laura Lauman, Division President, Proteomics and Small Molecule Business for Applied Biosystems. "Maximum sensitivity is a hallmark of our API product line and the API 5000(TM) LC/MS/MS System continues this tradition, combining robustness and reliability with the latest technology innovations for the most sensitive and accurate results for greater productivity."
The API 5000(TM) System is introduced in conjunction with Analyst(R) 1.4.1 Software, which offers automated features including sampling and data analysis for added ease-of-use and higher throughput. Analyst(R) 1.4.1 Software also adds groundbreaking tools to the Lab, allowing for seamless security, smooth network acquisition, and flexible but strong auditing capabilities. These features allow for efficient, integrated analysis in a networked environment, and assists with GLP and 21 CFR Part 11 requirements.
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.7 billion during fiscal 2004. The Celera Genomics Group (NYSE:CRA) is engaged principally in the discovery and development of targeted therapeutics for cancer, autoimmune and inflammatory diseases. Celera Genomics is leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop small molecule therapeutics. It is also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com/.
About MDS Sciex and MDS Inc.
MDS Sciex is the analytical instrumentation and technology solutions division of MDS Inc. At MDS Inc., our 10,000 highly skilled people provide services and products, which enable health sciences organizations to enhance the well being of people around the world. We focus on helping discover and test new drugs, assisting doctors to diagnose and treat patients and preventing the spread of disease. Find out more about MDS Inc. (TSX:MDS)(NYSE:MDZ), at www.mdsintl.com (http://mdsintl.com) or by calling 1-888-MDS-7222, 24 hours a day.
Applied Biosystems Forward Looking Statement
Certain statements in this press release are forward-looking and subject to a variety of risks and uncertainties. These may be identified by the use of forward-looking words or phrases such as "should" among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Applied Biosystems businesses include but are not limited to (1) rapidly changing technology and dependence on new products; (2) sales dependent on customers' capital spending policies and government-sponsored research; (3) claims for patent infringement; and (4) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission.
For Research Use Only. Not for use in diagnostic procedures.
Copyright(C) 2005. Applera Corporation and MDS Inc. All rights reserved. Applied Biosystems and Celera are registered trademarks and Applera, Celera Diagnostics, and Celera Genomics are trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries.
API 5000, QJet, and TurboV are trademarks and Analyst is a registered trademark of Applied Biosystems/MDS SCIEX, a joint venture between Applera Corporation and MDS Inc.
(1)Drug metabolism and pharmacokinetics
(2)Absorption, distribution, metabolism, excretion, toxicity
--30--NL/sf*
Business Editors/Health/Medical Writers
BIOWIRE2K
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 12, 2005--
Applied Biosystems (NYSE:ABI), an Applera Corporation business, together with its partner MDS Sciex (NYSE:MDZ)(TSX:MDS), today announced the release of the API 5000(TM) LC/MS/MS System, the latest addition to its API family of triple quadrupole analyzers. The API 5000(TM) LC/MS/MS System brings the most sensitive and accurate mass spectrometer to the market for small molecule quantification, which is essential for DMPK(1) and ADMET(2) studies. The system sets a new industry standard by achieving an average nine-fold increase in sensitivity and four-fold improvement in signal-to-noise ratio over other commercially available systems. The instrument will be unveiled to customers in demonstrations around the globe during the coming weeks.
"Pharmaceutical development and clinical research organizations require better tools for critical safety and efficacy studies. The improved sensitivity provided by the API 5000(TM) LC/MS/MS System increases the ability to assay a drug candidate, its metabolites or contaminants," said Catherine M. Burzik, President of Applied Biosystems. "This system can enable these groups to make better decisions during the costly process of bringing new drugs to market."
"The innovative QJet(TM) ion guide, introduced in the API 5000(TM) LC/MS/MS System, captures more ions and focuses the ion beam with high efficiency for improving ion transmission, yielding unparalleled sensitivity," said Andy Boorn, President of MDS Sciex. "This combination permits the use of smaller sample sizes, conserving often limited material for additional studies. When paired with the Turbo V(TM) ion source, users can easily increase flow rates and throughput without a corresponding loss in signal."
"Applied Biosystems/MDS SCIEX is proud to offer the next generation platform for bioanalytical research," said Laura Lauman, Division President, Proteomics and Small Molecule Business for Applied Biosystems. "Maximum sensitivity is a hallmark of our API product line and the API 5000(TM) LC/MS/MS System continues this tradition, combining robustness and reliability with the latest technology innovations for the most sensitive and accurate results for greater productivity."
The API 5000(TM) System is introduced in conjunction with Analyst(R) 1.4.1 Software, which offers automated features including sampling and data analysis for added ease-of-use and higher throughput. Analyst(R) 1.4.1 Software also adds groundbreaking tools to the Lab, allowing for seamless security, smooth network acquisition, and flexible but strong auditing capabilities. These features allow for efficient, integrated analysis in a networked environment, and assists with GLP and 21 CFR Part 11 requirements.
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.7 billion during fiscal 2004. The Celera Genomics Group (NYSE:CRA) is engaged principally in the discovery and development of targeted therapeutics for cancer, autoimmune and inflammatory diseases. Celera Genomics is leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop small molecule therapeutics. It is also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com/.
About MDS Sciex and MDS Inc.
MDS Sciex is the analytical instrumentation and technology solutions division of MDS Inc. At MDS Inc., our 10,000 highly skilled people provide services and products, which enable health sciences organizations to enhance the well being of people around the world. We focus on helping discover and test new drugs, assisting doctors to diagnose and treat patients and preventing the spread of disease. Find out more about MDS Inc. (TSX:MDS)(NYSE:MDZ), at www.mdsintl.com (http://mdsintl.com) or by calling 1-888-MDS-7222, 24 hours a day.
Applied Biosystems Forward Looking Statement
Certain statements in this press release are forward-looking and subject to a variety of risks and uncertainties. These may be identified by the use of forward-looking words or phrases such as "should" among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Applied Biosystems businesses include but are not limited to (1) rapidly changing technology and dependence on new products; (2) sales dependent on customers' capital spending policies and government-sponsored research; (3) claims for patent infringement; and (4) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission.
For Research Use Only. Not for use in diagnostic procedures.
Copyright(C) 2005. Applera Corporation and MDS Inc. All rights reserved. Applied Biosystems and Celera are registered trademarks and Applera, Celera Diagnostics, and Celera Genomics are trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries.
API 5000, QJet, and TurboV are trademarks and Analyst is a registered trademark of Applied Biosystems/MDS SCIEX, a joint venture between Applera Corporation and MDS Inc.
(1)Drug metabolism and pharmacokinetics
(2)Absorption, distribution, metabolism, excretion, toxicity
--30--NL/sf*
CONTACT: Applied Biosystems Lori Murray, 650-638-6130 (Media) murrayla@appliedbiosystems.com Linda Greub, 650-554-2349 (Investors) greublm@appliedbiosystems.com David Speechly, (+)44.162.273.9150 (European Media and Investors) speechdp@eur.appliedbiosystems.com or MDS Sciex Peter Schram, 416-675-6777 ext. 2141 (Media) pschram@mdaintl.com Sharon Mathers, 416-213-4721 (Investors) smathers@mdsintl.com
KEYWORD: CALIFORNIA INTERNATIONAL CANADA INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY PRODUCT MARKETING AGREEMENTS SOURCE: Applied Biosystems
Copyright Business Wire 2005
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Applera Corp. - Applied Biosystemsmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Applera Corp. - Applied Biosystemsmehr Analysen
Indizes in diesem Artikel
| NASDAQ Comp. | 19 161,63 | -1,63% | |
| S&P 500 | 5 827,04 | -1,54% |
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.